Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.
HEC
MEC
antiemetic regimen
breakthrough CINV
hydration costs
palonosetron
subcutaneous granisetron extended-release
Journal
American health & drug benefits
ISSN: 1942-2962
Titre abrégé: Am Health Drug Benefits
Pays: United States
ID NLM: 101479877
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
22
09
2020
accepted:
17
02
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
Granisetron extended-release subcutaneous (SC) injection is a novel formulation of granisetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Palonosetron is administered intravenously and is indicated for CINV prevention in acute and delayed phases after the use of moderately emetogenic chemotherapy (MEC) and in the acute phase after highly emetogenic chemotherapy (HEC). No data are available regarding the impact of SC granisetron on the cost of unscheduled hydration compared with other antiemetic drugs, specifically the older-generation palonosetron. To compare the costs of unscheduled hydration associated with breakthrough CINV after SC granisetron versus palonosetron administration in patients receiving MEC or HEC. This retrospective analysis was based on electronic medical records data from a single multicenter, community-based practice involving patients receiving MEC or HEC with a 3-drug antiemetic regimen, including a neurokinin-1 receptor antagonist, dexamethasone, and either SC granisetron or palonosetron. A cost-of-care analysis for SC granisetron and palonosetron was based on the maximum per-unit Medicare reimbursement amounts for the use of unscheduled hydration, administration of rescue antiemetic drugs, laboratory tests, and patient office evaluations. A total of 182 patient records were evaluated, 91 for patients receiving SC granisetron and 91 receiving palonosetron. The mean per-patient cost of care related to unscheduled hydration in patients receiving HEC or MEC was significantly lower with SC granisetron ($296) than palonosetron ($837; The use of SC granisetron reduced the total per-patient costs of care associated with unscheduled hydration compared with palonosetron in patients receiving HEC or MEC for breakthrough CINV events.
Sections du résumé
Background
UNASSIGNED
Granisetron extended-release subcutaneous (SC) injection is a novel formulation of granisetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Palonosetron is administered intravenously and is indicated for CINV prevention in acute and delayed phases after the use of moderately emetogenic chemotherapy (MEC) and in the acute phase after highly emetogenic chemotherapy (HEC). No data are available regarding the impact of SC granisetron on the cost of unscheduled hydration compared with other antiemetic drugs, specifically the older-generation palonosetron.
Objective
UNASSIGNED
To compare the costs of unscheduled hydration associated with breakthrough CINV after SC granisetron versus palonosetron administration in patients receiving MEC or HEC.
Methods
UNASSIGNED
This retrospective analysis was based on electronic medical records data from a single multicenter, community-based practice involving patients receiving MEC or HEC with a 3-drug antiemetic regimen, including a neurokinin-1 receptor antagonist, dexamethasone, and either SC granisetron or palonosetron. A cost-of-care analysis for SC granisetron and palonosetron was based on the maximum per-unit Medicare reimbursement amounts for the use of unscheduled hydration, administration of rescue antiemetic drugs, laboratory tests, and patient office evaluations.
Results
UNASSIGNED
A total of 182 patient records were evaluated, 91 for patients receiving SC granisetron and 91 receiving palonosetron. The mean per-patient cost of care related to unscheduled hydration in patients receiving HEC or MEC was significantly lower with SC granisetron ($296) than palonosetron ($837;
Conclusion
UNASSIGNED
The use of SC granisetron reduced the total per-patient costs of care associated with unscheduled hydration compared with palonosetron in patients receiving HEC or MEC for breakthrough CINV events.
Types de publication
Journal Article
Langues
eng
Pagination
1-7Informations de copyright
Copyright © 2021 by Engage Healthcare Communications, LLC.
Références
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
Support Care Cancer. 2015 Mar;23(3):723-32
pubmed: 25179689
Support Care Cancer. 2017 Jan;25(1):277-288
pubmed: 27443154
Biomed Res Int. 2015;2015:595894
pubmed: 26421294
J Exp Pharmacol. 2014 Dec 09;6:15-21
pubmed: 27186139
Support Care Cancer. 2011 Jan;19(1):131-40
pubmed: 20101417
Future Oncol. 2016 Jun;12(12):1469-81
pubmed: 26997579
Future Oncol. 2019 Mar;15(7):753-761
pubmed: 30499739
Future Oncol. 2018 Jun;14(14):1387-1396
pubmed: 29421926
Support Care Cancer. 2007 May;15(5):497-503
pubmed: 17103197
Support Care Cancer. 2011 Jun;19(6):843-51
pubmed: 20532923
Cancer Manag Res. 2015 Mar 17;7:83-92
pubmed: 25834466
Br J Pharmacol. 1995 Feb;114(4):860-6
pubmed: 7773547
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
Future Oncol. 2020 Aug;16(24):1863-1872
pubmed: 32543309
J Clin Oncol. 2006 Sep 20;24(27):4472-8
pubmed: 16983116
Support Care Cancer. 2014 Feb;22(2):469-77
pubmed: 24141698
Support Care Cancer. 2015 Jan;23(1):151-7
pubmed: 25015057
Expert Opin Pharmacother. 2013 Apr;14(6):757-66
pubmed: 23496347
Crit Rev Oncol Hematol. 2016 Mar;99:13-36
pubmed: 26697988
Support Care Cancer. 2012 Jan;20(1):107-17
pubmed: 21258948
Cancer Manag Res. 2018 Jul 03;10:1827-1857
pubmed: 30013391
Am Health Drug Benefits. 2014 Jan;7(1):50-8
pubmed: 24991390
Future Oncol. 2015 Sep;11(18):2541-51
pubmed: 26289588
Cancer. 2007 Aug 1;110(3):678-85
pubmed: 17567835
Am Health Drug Benefits. 2015 Jul-Aug;8(5):273-82
pubmed: 26380034